Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 231-238

  Cooke, Catherine E ^a,b   Lee, Helen Y ^c   Tong, Yvette P ^b   Haines, Stuart T ^b  

^a PosiHealth   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c CareFirst BlueCross BlueShield   (United States)

Author keywords

Diabetes mellitus, type 2; Hypoglycemic agents; Insulin; Medication adherence

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; RELION N; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; HEALTH CARE ORGANIZATION; HOSPITAL PHARMACY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PRESCRIPTION; SURVIVAL RATE; TREATMENT OUTCOME; AGED; DRUG USE; HEALTH INSURANCE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATIENT COMPLIANCE;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAMUSCULAR; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 77649222220     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903421994     Document Type: Article

References (19)

1. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf [Last accessed 25 September 2009]
2. American Diabetes Association. Standards of medical care in diabetes -2008 ( position statement). Diabetes Care 2008;31:S12-S54
3. Koro CE, Bowlin SJ., Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20 (Pubitemid 38196703)
4. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-72 (Pubitemid 44156663)
5. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005;28:2673-9
6. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial. Diabetes Care 2003;26:3080-6
7. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357:1716-30 (Pubitemid 350005153)
8. Boccuzzi SJ, Sung JCY, Wogen J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001; 24:1411-15 (Pubitemid 33716429)
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24 (Pubitemid 38579798)
10. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87 (Pubitemid 350294021)
11. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003; 25:2958-71 (Pubitemid 37510603)
12. Erickson TN, Devine EB, O'Young TS, et al. Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine. Am J Health Syst Pharm 2006;63:1862-71 (Pubitemid 44477458)
13. Heine RJ, Van Gaal LF, Johns D et al., for the GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-69
14. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane Library 2007 Apr 18:CD005613
15. Hermansen K, Clauson P, Davies M, et al. on behalf of the Levemir Treat-to-Target study group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74 (Pubitemid 44125921)
16. Rosenstock J, Schwartz SL, Clark Jr. CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-36 (Pubitemid 32888839)
17. Donnelly LA, Morris AD, Evans JMM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100: 345-50 (Pubitemid 47073810)
18. Piette JD. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004;27:384-91 (Pubitemid 38174062)
19. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations. Med Care 2005; 43:951-9 (Pubitemid 41442460)